Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Smith & Nephew Plc
  6. News
  7. Summary
    SN.   GB0009223206


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith & Nephew : Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of - Form 6-K

10/22/2021 | 06:54am EST
Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of
Yes No X
--- ---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b) : 82- n/a.
Smith+Nephew to host Meet the Management event
22 October 2021
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announces that it will be holding a virtual Meet the Management event for institutional investors and analysts from 12:30pm GMT (7:30am EST) on 16 December 2021.
The event will consist of a formal presentation, followed by break-out group meetings with members of the senior leadership team including the Chief Executive Officer, Chief Financial Officer, and Presidents of the global franchises.
Institutional investors or analysts wishing to take part should register on the Smith+Nephew corporate website: www.smith-nephew.com/meetthemanagement.
Additionally, the formal presentation will be streamed live with a replay available after the event.
Investors/ Analysts
Andrew Swift +44 (0) 1923 477433
Charles Reynolds +44 (0) 1923 477314
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.


Smith & Nephew plc published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 10:53:10 UTC.

ę Publicnow 2021
All news about SMITH & NEPHEW PLC
11/24Smith+Nephew launches Real Intelligence and CORI™ Surgical System; next generatio..
11/24Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Ha..
11/24Smith+Nephew launches 'turn-key' robotic-assisted surgical system; designed to quickly ..
11/23Smith & Nephew Unveils New Robotic-Assisted System for Knee Surgery
11/23Smith+Nephew Launches CORI Handheld Robotics
11/16Smith & Nephew plc Announces Digital Surgery and Robotics Innovation Centre in Europe
11/12European ADRs Move Lower in Friday Trading
11/09Smith+Nephew Establishes Its First Medical Education Centre for the Asia Pacific Region..
11/05European ADRs Flat Friday as Travel Stocks Rise, Pharma Falls
11/05Berenberg Cuts Smith & Nephew PT, Affirms Buy Rating
More news
Analyst Recommendations on SMITH & NEPHEW PLC
More recommendations
Financials (USD)
Sales 2021 5 258 M - -
Net income 2021 430 M - -
Net Debt 2021 1 781 M - -
P/E ratio 2021 32,2x
Yield 2021 2,15%
Capitalization 14 481 M 14 493 M -
EV / Sales 2021 3,09x
EV / Sales 2022 2,84x
Nbr of Employees 18 000
Free-Float 99,1%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 16,48 $
Average target price 21,01 $
Spread / Average Target 27,4%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Roberto Quarta Chairman
Vasant Padmanabhan President-Research & Development
Paul Connolly President-Global Operations
Sector and Competitors